{"filing":{"accession_number":"0001193125-26-385355","cik":"0001745648","ticker":null,"company_name":"Apnimed, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"apmd-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-20260908.htm"},"events":[{"id":32076,"run_id":29465,"accession_number":"0001193125-26-385355","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 \"Results of Operations and Financial Condition.\" The press release announces quarterly financial results including revenue, operating expenses, net income, and cash position, with the full text furnished as Exhibit 99.1. The disclosure is material as it reports significant financial performance including a $125.9 million net income swing and $172.8 million in cash, alongside material corporate developments (FDA NDA acceptance, IPO completion for $220.8 million gross proceeds).","company_name":"Apnimed, Inc.","ticker":null,"filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35154,"accession_number":"0001193125-26-385355","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 \"Results of Operations and Financial Condition.\" The press release announces quarterly financial results including revenue, operating expenses, net income, and cash position, with the full text furnished as Exhibit 99.1. The disclosure is material as it reports significant financial performance including a $125.9 million net income swing and $172.8 million in cash, alongside material corporate developments (FDA NDA acceptance, IPO completion for $220.8 million gross proceeds).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:11:38.680297+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35154,"accession_number":"0001193125-26-385355","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 \"Results of Operations and Financial Condition.\" The press release announces quarterly financial results including revenue, operating expenses, net income, and cash position, with the full text furnished as Exhibit 99.1. The disclosure is material as it reports significant financial performance including a $125.9 million net income swing and $172.8 million in cash, alongside material corporate developments (FDA NDA acceptance, IPO completion for $220.8 million gross proceeds).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:11:38.680297+00:00","company_name":"Apnimed, Inc.","ticker":null,"filing_date":"2026-09-08"}]}